This article is more than 5 years old. Information may no longer be current.
Autologous serum eye drops safe, effective for dry eye
Click Here to Manage Email Alerts
Researchers determined that 50% autologous serum eye drops were both effective and safe as a long-term treatment option for dry eye disease in a study recently published in Cornea.
Hussain and colleagues conducted a retrospective cohort study that included 123 eyes of 63 patients.
Researchers examined participants' records for dry eye etiology, adverse events, symptoms and clinical history. Participants underwent ocular evaluations that included ocular surface disease index, fluorescein staining and Schirmer’s testing with topical anesthesia.
They assessed the data collected at the baseline visit as well as at 1 month and every 3 to 6 months during the treatment with the 50% autologous serum eye drops.
Results showed improvements in several measurements as well as no complications from the treatment.
"In this study, we investigated the safety and effectiveness of the long-term use of autologous serum eye drops in a large cohort of patients with dry eye disease who were refractory to conventional treatments," the authors detailed. "Schirmer’s scores and fluorescein staining improved in our population of patients, especially during the first year, and all patients reported subjective improvement with the use of autologous serum. Using linear mixed regression models, Schirmer’s scores showed a significant trend of improvement over time.
“Dry eye disease has a known inflammatory component, and the growth factors in serum tears can reduce inflammation,” they continued. “Because Schirmer’s scores increase with anti-inflammatory treatments, this is consistent in this study with the use of serum eye drops."
They concluded: "In summary, 50% autologous serum eye drops seem to be safe and effective for long-term treatment of dry eye disease. They are a valuable option in patients with severe dry disease who have exhausted conventional forms of treatment."
Disclosure: The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts